{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:37:07Z","timestamp":1773275827882,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"CNPq and CAPES","award":["BEX6726\/15-1"],"award-info":[{"award-number":["BEX6726\/15-1"]}]},{"name":"FEDER AND POCI","award":["POCI-01-0145-FEDER-007274"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007274"]}]},{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","award":["NORTE-01-0145-FEDER-000029"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000029"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","award":["Grant PI15 \/ 01501-FEDER"],"award-info":[{"award-number":["Grant PI15 \/ 01501-FEDER"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s12020-018-1642-0","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T07:09:20Z","timestamp":1529046560000},"page":"489-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma"],"prefix":"10.1007","volume":"61","author":[{"given":"Gustavo C.","family":"Penna","sequence":"first","affiliation":[]},{"given":"Ana","family":"Pestana","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Manuel","family":"Cameselle","sequence":"additional","affiliation":[]},{"given":"Denise","family":"Momesso","sequence":"additional","affiliation":[]},{"given":"Fernanda Accioly","family":"de Andrade","sequence":"additional","affiliation":[]},{"given":"Ana Paula Aguiar","family":"Vidal","sequence":"additional","affiliation":[]},{"given":"Mario Lucio","family":"Araujo Junior","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Melo","sequence":"additional","affiliation":[]},{"given":"Priscila Valverde","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Rossana","family":"Corbo","sequence":"additional","affiliation":[]},{"given":"Mario","family":"Vaisman","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Sobrinho-Sim\u00f5es","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-7108","authenticated-orcid":false,"given":"Fernanda","family":"Vaisman","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"1642_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3185","volume":"4","author":"J Vinagre","year":"2013","unstructured":"J. Vinagre, A. Almeida, H. Populo, R. Batista, J. Lyra, V. Pinto, R. Coelho, R. Celestino, H. Prazeres, L. Lima, M. Melo, A.G. da Rocha, A. Preto, P. Castro, L. Castro, F. Pardal, J.M. Lopes, L.L. Santos, R.M. Reis, J. Cameselle-Teijeiro, M. Sobrinho-Simoes, J. Lima, V. Maximo, P. Soares, Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013). \n                    https:\/\/doi.org\/10.1038\/ncomms3185","journal-title":"Nat. Commun."},{"issue":"6122","key":"1642_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"S. Horn, A. Figl, P.S. Rachakonda, C. Fischer, A. Sucker, A. Gast, S. Kadel, I. Moll, E. Nagore, K. Hemminki, D. Schadendorf, R. Kumar, TERT promoter mutations in familial and sporadic melanoma. Science 339(6122), 959\u2013961 (2013). \n                    https:\/\/doi.org\/10.1126\/science.1230062","journal-title":"Science"},{"issue":"6122","key":"1642_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"F.W. Huang, E. Hodis, M.J. Xu, G.V. Kryukov, L. Chin, L.A. Garraway, Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122), 957\u2013959 (2013). \n                    https:\/\/doi.org\/10.1126\/science.1229259","journal-title":"Science"},{"issue":"15","key":"1642_CR4","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"P.J. Killela, Z.J. Reitman, Y. Jiao, C. Bettegowda, N. Agrawal, L.A. Diaz Jr., A.H. Friedman, H. Friedman, G.L. Gallia, B.C. Giovanella, A.P. Grollman, T.C. He, Y. He, R.H. Hruban, G.I. Jallo, N. Mandahl, A.K. Meeker, F. Mertens, G.J. Netto, B.A. Rasheed, G.J. Riggins, T.A. Rosenquist, M. Schiffman, M. Shih Ie, D. Theodorescu, M.S. Torbenson, V.E. Velculescu, T.L. Wang, N. Wentzensen, L.D. Wood, M. Zhang, R.E. McLendon, D.D. Bigner, K.W. Kinzler, B. Vogelstein, N. Papadopoulos, H. Yan, TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. USA 110(15), 6021\u20136026 (2013). \n                    https:\/\/doi.org\/10.1073\/pnas.1303607110","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"1642_CR5","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1530\/JME-16-0195","volume":"58","author":"A Pestana","year":"2017","unstructured":"A. Pestana, J. Vinagre, M. Sobrinho-Simoes, P. Soares, TERT biology and function in cancer: beyond immortalisation. J. Mol. Endocrinol. 58(2), R129\u2013R146 (2017). \n                    https:\/\/doi.org\/10.1530\/JME-16-0195","journal-title":"J. Mol. Endocrinol."},{"issue":"5","key":"1642_CR6","doi-asserted-by":"publisher","first-page":"E754","DOI":"10.1210\/jc.2013-3734","volume":"99","author":"M Melo","year":"2014","unstructured":"M. Melo, A.G. da Rocha, J. Vinagre, R. Batista, J. Peixoto, C. Tavares, R. Celestino, A. Almeida, C. Salgado, C. Eloy, P. Castro, H. Prazeres, J. Lima, T. Amaro, C. Lobo, M.J. Martins, M. Moura, B. Cavaco, V. Leite, J.M. Cameselle-Teijeiro, F. Carrilho, M. Carvalheiro, V. Maximo, M. Sobrinho-Simoes, P. Soares, TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 99(5), E754\u2013E765 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2013-3734","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5193","key":"1642_CR7","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1126\/science.7605428","volume":"266","author":"NW Kim","year":"1994","unstructured":"N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L. Ho, G.M. Coviello, W.E. Wright, S.L. Weinrich, J.W. Shay, Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193), 2011\u20132015 (1994)","journal-title":"Science"},{"issue":"9","key":"1642_CR8","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","volume":"98","author":"I Landa","year":"2013","unstructured":"I. Landa, I. Ganly, T.A. Chan, N. Mitsutake, M. Matsuse, T. Ibrahimpasic, R.A. Ghossein, J.A. Fagin, Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J. Clin. Endocrinol. Metab. 98(9), E1562\u2013E1566 (2013). \n                    https:\/\/doi.org\/10.1210\/jc.2013-2383","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"1642_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/ERC-13-0210","volume":"20","author":"X Liu","year":"2013","unstructured":"X. Liu, J. Bishop, Y. Shan, S. Pai, D. Liu, A.K. Murugan, H. Sun, A.K. El-Naggar, M. Xing, Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr. Relat. Cancer 20(4), 603\u2013610 (2013). \n                    https:\/\/doi.org\/10.1530\/ERC-13-0210","journal-title":"Endocr. Relat. Cancer"},{"issue":"6","key":"1642_CR10","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","volume":"99","author":"X Liu","year":"2014","unstructured":"X. Liu, S. Qu, R. Liu, C. Sheng, X. Shi, G. Zhu, A.K. Murugan, H. Guan, H. Yu, Y. Wang, H. Sun, Z. Shan, W. Teng, M. Xing, TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J. Clin. Endocrinol. Metab. 99(6), E1130\u2013E1136 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2013-4048","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"25","key":"1642_CR11","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","volume":"32","author":"M Xing","year":"2014","unstructured":"M. Xing, R. Liu, X. Liu, A.K. Murugan, G. Zhu, M.A. Zeiger, S. Pai, J. Bishop, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J. Clin. Oncol. 32(25), 2718\u20132726 (2014). \n                    https:\/\/doi.org\/10.1200\/JCO.2014.55.5094","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"1642_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1530\/ERC-15-0396","volume":"22","author":"E Qasem","year":"2015","unstructured":"E. Qasem, A.K. Murugan, H. Al-Hindi, M. Xing, M. Almohanna, M. Alswailem, A.S. Alzahrani, TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr. Relat. Cancer 22(6), 901\u2013908 (2015). \n                    https:\/\/doi.org\/10.1530\/ERC-15-0396","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"1642_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/cen.12999","volume":"85","author":"M Bullock","year":"2016","unstructured":"M. Bullock, Y. Ren, C. O\u2019Neill, A. Gill, A. Aniss, M. Sywak, S. Sidhu, L. Delbridge, D. Learoyd, F. de Vathaire, B.G. Robinson, R.J. Clifton-Bligh, TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clin. Endocrinol. 85(2), 283\u2013290 (2016). \n                    https:\/\/doi.org\/10.1111\/cen.12999","journal-title":"Clin. Endocrinol."},{"issue":"12","key":"1642_CR14","doi-asserted-by":"publisher","first-page":"E1550","DOI":"10.1210\/jc.2015-2690","volume":"100","author":"JR George","year":"2015","unstructured":"J.R. George, Y.C. Henderson, M.D. Williams, D.B. Roberts, H. Hei, S.Y. Lai, G.L. Clayman, Association of TERT promoter mutation, but Not BRAF mutation, with increased mortality in PTC. J. Clin. Endocrinol. Metab. 100(12), E1550\u2013E1559 (2015). \n                    https:\/\/doi.org\/10.1210\/jc.2015-2690","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"1642_CR15","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1210\/jc.2016-2785","volume":"102","author":"M Melo","year":"2017","unstructured":"M. Melo, A. Gaspar da Rocha, R. Batista, J. Vinagre, M.J. Martins, G. Costa, C. Ribeiro, F. Carrilho, V. Leite, C. Lobo, J.M. Cameselle-Teijeiro, B. Cavadas, L. Pereira, M. Sobrinho-Simoes, P. Soares, TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease. J. Clin. Endocrinol. Metab. 102(6), 1898\u20131907 (2017). \n                    https:\/\/doi.org\/10.1210\/jc.2016-2785","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"42","key":"1642_CR16","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1038\/onc.2013.446","volume":"33","author":"T Liu","year":"2014","unstructured":"T. Liu, N. Wang, J. Cao, A. Sofiadis, A. Dinets, J. Zedenius, C. Larsson, D. Xu, The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33(42), 4978\u20134984 (2014). \n                    https:\/\/doi.org\/10.1038\/onc.2013.446","journal-title":"Oncogene"},{"issue":"4","key":"1642_CR17","doi-asserted-by":"publisher","first-page":"E632","DOI":"10.1210\/jc.2014-3606","volume":"100","author":"X Shi","year":"2015","unstructured":"X. Shi, R. Liu, S. Qu, G. Zhu, J. Bishop, X. Liu, H. Sun, Z. Shan, E. Wang, Y. Luo, X. Yang, J. Zhao, J. Du, A.K. El-Naggar, W. Teng, M. Xing, Association of TERT promoter mutation 1,295,228 C T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 100(4), E632\u2013E637 (2015). \n                    https:\/\/doi.org\/10.1210\/jc.2014-3606","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"1642_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"I. Landa, T. Ibrahimpasic, L. Boucai, R. Sinha, J.A. Knauf, R.H. Shah, S. Dogan, J.C. Ricarte-Filho, G.P. Krishnamoorthy, B. Xu, N. Schultz, M.F. Berger, C. Sander, B.S. Taylor, R. Ghossein, I. Ganly, J.A. Fagin, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126(3), 1052\u20131066 (2016). \n                    https:\/\/doi.org\/10.1172\/JCI85271","journal-title":"J. Clin. Invest."},{"issue":"4","key":"1642_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1530\/EJE-14-0837","volume":"172","author":"G Gandolfi","year":"2015","unstructured":"G. Gandolfi, M. Ragazzi, A. Frasoldati, S. Piana, A. Ciarrocchi, V. Sancisi, TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur. J. Endocrinol. 172(4), 403\u2013413 (2015). \n                    https:\/\/doi.org\/10.1530\/EJE-14-0837","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"1642_CR20","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/ERC-17-0453","volume":"25","author":"L Lamartina","year":"2018","unstructured":"L. Lamartina, G. Grani, E. Arvat, A. Nervo, M.C. Zatelli, R. Rossi, E. Puxeddu, S. Morelli, M. Torlontano, M. Massa, R. Bellantone, A. Pontecorvi, T. Montesano, L. Pagano, L. Daniele, L. Fugazzola, G. Ceresini, R. Bruno, R. Rossetto, S. Tumino, M. Centanni, D. Meringolo, M.G. Castagna, D. Salvatore, A. Nicolucci, G. Lucisano, S. Filetti, C. Durante, 8th edition of the AJCC\/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr. Relat. Cancer 25(3), L7\u2013L11 (2018). \n                    https:\/\/doi.org\/10.1530\/ERC-17-0453","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"1642_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1\u2013133 (2016). \n                    https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"issue":"5","key":"1642_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","volume":"2","author":"M Schlumberger","year":"2014","unstructured":"M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia, F. Pacini, Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356\u2013358 (2014). \n                    https:\/\/doi.org\/10.1016\/S2213-8587(13)70215-8","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"1642_CR23","doi-asserted-by":"publisher","first-page":"E754","DOI":"10.1210\/jc.2013-3734","volume":"99","author":"M Melo","year":"2014","unstructured":"M. Melo, A.G. da Rocha, J. Vinagre, R. Batista, J. Peixoto, C. Tavares, R. Celestino, A. Almeida, C. Salgado, C. Eloy, P. Castro, H. Prazeres, J. Lima, T. Amaro, C. Lobo, M.J. Martins, M. Moura, B. Cavaco, V. Leite, J.M. Cameselle-Teijeiro, F. Carrilho, M. Carvalheiro, V. M\u00e1ximo, M. Sobrinho-Sim\u00f5es, P. Soares, TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 99(5), E754\u2013E765 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"29","key":"1642_CR24","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1038\/sj.onc.1206706","volume":"22","author":"P Soares","year":"2003","unstructured":"P. Soares, V. Trovisco, A.S. Rocha, J. Lima, P. Castro, A. Preto, V. M\u00e1ximo, T. Botelho, R. Seruca, M. Sobrinho-Sim\u00f5es, BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22(29), 4578\u20134580 (2003)","journal-title":"Oncogene"},{"issue":"12","key":"1642_CR25","doi-asserted-by":"publisher","first-page":"13680","DOI":"10.18632\/oncotarget.7322","volume":"7","author":"JH Kim","year":"2016","unstructured":"J.H. Kim, Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. Oncotarget 7(12), 13680\u201313687 (2016). \n                    https:\/\/doi.org\/10.18632\/oncotarget.7322","journal-title":"Oncotarget"},{"issue":"2","key":"1642_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3892\/ol.2013.1424","volume":"6","author":"M Ruan","year":"2013","unstructured":"M. Ruan, Y. Shen, L. Chen, M. Li, RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma. Oncol. Lett. 6(2), 480\u2013486 (2013). \n                    https:\/\/doi.org\/10.3892\/ol.2013.1424","journal-title":"Oncol. Lett."},{"issue":"4","key":"1642_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1365-2265.2008.03243.x","volume":"69","author":"V Trovisco","year":"2008","unstructured":"V. Trovisco, J.P. Couto, J. Cameselle-Teijeiro, I.V. de Castro, E. Fonseca, P. Soares, M. Sobrinho-Simoes, Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin. Endocrinol. 69(4), 683\u2013685 (2008). \n                    https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03243.x","journal-title":"Clin. Endocrinol."},{"issue":"6","key":"1642_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00428-005-1236-0","volume":"446","author":"V Trovisco","year":"2005","unstructured":"V. Trovisco, P. Soares, A. Preto, I.V. de Castro, J. Lima, P. Castro, V. Maximo, T. Botelho, S. Moreira, A.M. Meireles, J. Magalhaes, A. Abrosimov, J. Cameselle-Teijeiro, M. Sobrinho-Simoes, Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients\u2019 age but not with tumour aggressiveness. Virchows. Arch. 446(6), 589\u2013595 (2005). \n                    https:\/\/doi.org\/10.1007\/s00428-005-1236-0","journal-title":"Virchows. Arch."},{"issue":"3","key":"1642_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00428-011-1133-7","volume":"459","author":"C Eloy","year":"2011","unstructured":"C. Eloy, J. Santos, P. Soares, M. Sobrinho-Simoes, The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows. Arch. 459(3), 265\u2013276 (2011). \n                    https:\/\/doi.org\/10.1007\/s00428-011-1133-7","journal-title":"Virchows. Arch."},{"issue":"9","key":"1642_CR30","doi-asserted-by":"publisher","first-page":"E1745","DOI":"10.1210\/jc.2012-1526","volume":"97","author":"V Sancisi","year":"2012","unstructured":"V. Sancisi, D. Nicoli, M. Ragazzi, S. Piana, A. Ciarrocchi, BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J. Clin. Endocrinol. Metab. 97(9), E1745\u2013E1749 (2012). \n                    https:\/\/doi.org\/10.1210\/jc.2012-1526","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"1642_CR31","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1001\/jamaoto.2013.4501","volume":"139","author":"C Gouveia","year":"2013","unstructured":"C. Gouveia, N.T. Can, A. Bostrom, J.P. Grenert, A. van Zante, L.A. Orloff, Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol. Head. Neck Surg. 139(11), 1164\u20131170 (2013). \n                    https:\/\/doi.org\/10.1001\/jamaoto.2013.4501","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"1642_CR32","doi-asserted-by":"crossref","unstructured":"R. Bu, A.K. Siraj, S.P. Divya, Y. Kong, S.K. Parvathareddy, M. Al-Rasheed, K.A.S. Al-Obaisi, I.G. Victoria, S.S. Al-Sobhi, M. Al-Dawish, F. Al-Dayel, K.S. Al-Kuraya, Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer. Int. J. Cancer (2017). https:\/\/doi.org\/10.1002\/ijc.31225","DOI":"10.1002\/ijc.31225"},{"key":"1642_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2017.12.027","volume":"92","author":"C Fouchardiere de la","year":"2018","unstructured":"C. de la Fouchardiere, M. Decaussin-Petrucci, J. Berthiller, F. Descotes, J. Lopez, J.C. Lifante, J.L. Peix, A.L. Giraudet, A. Delahaye, S. Masson, C. Bournaud-Salinas, F. Borson Chazot, Predictive factors of outcome in poorly differentiated thyroid carcinomas. Eur. J. Cancer 92, 40\u201347 (2018). \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.12.027","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"1642_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1530\/EC-17-0302","volume":"7","author":"C Tavares","year":"2018","unstructured":"C. Tavares, M.J. Coelho, C. Eloy, M. Melo, A.G. da Rocha, A. Pestana, R. Batista, L.B. Ferreira, E. Rios, S. Selmi-Ruby, B. Cavadas, L. Pereira, M. Sobrinho Simoes, P. Soares, NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr. Connect. 7(1), 78\u201390 (2018). \n                    https:\/\/doi.org\/10.1530\/EC-17-0302","journal-title":"Endocr. Connect."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1642-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1642-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1642-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T19:24:31Z","timestamp":1560540271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1642-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1642-0","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]},"assertion":[{"value":"17 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}